|
| 36541754 | Incidence and survival of soft tissue sarcoma in England between 2013 and 2017, an analysis from the National Cancer Registration and Analysis Service. | Int J Cancer | 2023 |
| 37684354 | Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata. | Br J Cancer | 2023 |
| 37220319 | Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas. | Am Soc Clin Oncol Educ Book | 2023 |
| 37178646 | Primary retroperitoneal sarcoma: A comparison of survival outcomes in specialist and non-specialist sarcoma centres. | Eur J Cancer | 2023 |
| 34767314 | Current approaches to management of bone sarcoma in adolescent and young adult patients. | Pediatr Blood Cancer | 2022 |
| 35672690 | Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial). | BMC Cancer | 2022 |
| 35635934 | Survival after high-dose chemotherapy for refractory and recurrent Ewing sarcoma. | Eur J Cancer | 2022 |
| 35421838 | Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. | Eur J Cancer | 2022 |
| 36522207 | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. | Lancet | 2022 |
| 36585406 | Author Correction: Osteosarcoma. | Nat Rev Dis Primers | 2022 |
| 36481668 | Osteosarcoma. | Nat Rev Dis Primers | 2022 |
| 36138226 | Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone. | Cell Death Differ | 2022 |
| 35863108 | Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36031697 | Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. | Cancer Treat Rev | 2022 |
| 33289920 | SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. | Cancer | 2021 |
| 34862364 | Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. | Nat Commun | 2021 |
| 34392187 | Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. | Eur J Cancer | 2021 |
| 34562750 | Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)<sup>â¿¿</sup>. | ESMO Open | 2021 |
| 34416158 | Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. | Lancet Oncol | 2021 |
| 34303806 | Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>â¿¿</sup>. | Ann Oncol | 2021 |
| 33989031 | The diagnosis of pulmonary metastases on chest computed tomography in primary bone sarcoma and musculoskeletal soft tissue sarcoma. | Br J Radiol | 2021 |
| 34209887 | Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)? | Cancers (Basel) | 2021 |
| 34059352 | Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT). | Lung Cancer | 2021 |
| 34090171 | Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. | ESMO Open | 2021 |
| 34050156 | Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. | Nat Commun | 2021 |
| 32391141 | Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. | Clin Sarcoma Res | 2020 |
| 31952545 | International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. | Trials | 2020 |
| 33344901 | Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors. | ACS Pharmacol Transl Sci | 2020 |
| 33212978 | Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis. | Cancers (Basel) | 2020 |
| 32573957 | Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. | J Pathol Clin Res | 2020 |
| 32823999 | Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic. | Cancers (Basel) | 2020 |
| 32986243 | Cancer care and well-being in adolescents and young adults during the coronavirus disease 2019 pandemic: A UK sarcoma perspective. | Cancer | 2020 |
| 29741569 | Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. | Ann Oncol | 2019 |
| 30685685 | Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. | Eur J Cancer | 2019 |
| 29216400 | Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'. | Ann Oncol | 2018 |
| 30131505 | Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. | Sci Rep | 2018 |
| 30006631 | Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. | Sci Rep | 2018 |
| 30285218 | Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2018 |
| 29782347 | Current questions in bone sarcomas. | Curr Opin Oncol | 2018 |
| 29669701 | Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. | Lancet Respir Med | 2018 |
| 29567632 | The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'. | Eur J Cancer | 2018 |
| 28882536 | Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. | Lancet Oncol | 2017 |
| 28950372 | Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. | Ann Oncol | 2017 |
| 26947069 | Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. | Cell Rep | 2016 |
| 27315524 | The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. | Clin Sarcoma Res | 2016 |
| 27154292 | Follow-up practices for high-grade extremity Osteosarcoma. | BMC Cancer | 2016 |
| 27569442 | Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. | Lancet Oncol | 2016 |
| 27102572 | EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. | J Pathol | 2016 |
| 23670570 | Outcome after radiofrequency ablation of sarcoma lung metastases. | Cardiovasc Intervent Radiol | 2014 |
| 25281719 | Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. | Cancer Res | 2014 |